Ovarian Cancer | PARP Inhibitors
Estimated new cases and deaths from ovarian cancer in the United States in 2013:
- New cases: 22,240
- Deaths: 14,030
Dr. Birrer on PARP Inhibitors in Ovarian Cancer
NIH study uncovers new mechanism of action for class of chemotherapy drugs
National Institutes of Health (NIH) researchers have discovered a significant new mechanism of action for a class of chemotherapy drugs known as poly (ADP-ribose) polymerase inhibitors, or PARP inhibitors. They have also identified differences in the toxic capabilities of three drugs in this class which are currently being tested in clinical trials. The study, by scientists at the National Cancer Institute (NCI), part of NIH, and their colleagues, appeared in Cancer Research, Nov 1, 2012. Read more here >>
A Pharmacokinetic/Pharmacodynamic Study With a Phase I Run-In With a PARP Inhibitor (Olaparib) in Combination With Carboplatin for Refractory or Recurrent Women’s Cancers
Protocol # 11-C-0022, NCT01237067
- Why is this trial important?
- Who is eligible for this trial?
- What types of drugs or therapies are being used?
- What is the study outline?
- What is the frequency and duration of the visits?
- What are the costs?
- Where is this trial taking place?
- Who are the contacts for this trial?
- Where can additional information be found?
Olaparib is an experimental anti-cancer drug that is part of a class of drugs called poly (ADP-ribose) polymerase (PARP) inhibitors. PARP is a protein that is involved in repairing DNA damage, but it may also encourage precancerous cells to develop into cancer cells. Olaparib has been given safely in combination with carboplatin, a drug used to treat breast, ovarian, uterine, and cervical cancer, but more research is needed to determine which drug should be given first or whether the drugs are more effective when given together.
Where can additional information be found?
- Solid Tumor Trial NCI-11-C-0022, NCT01237067